HIV prevention model in Zambian prisons may be extended to other criminal justice facilities

A recent study performed in Zambia by University of Maryland School of Medicine's (UMSOM) Institute of Human Virology researchers found that high uptake of HIV preventative medicine, known as pre-exposure prophylaxis (PrEP), is possible in prison populations with adequate resources and support from the criminal justice health system.

In Sub-Saharan Africa, HIV infection disproportionately affects people detained within the criminal justice system. These vulnerable populations may not access regular medical care before and during incarceration.

Published in the January 2023 issue of The Lancet HIV, the research team provided evidence of a model HIV prevention with at-risk populations that could possibly be extended to other criminal justice facilities, as many of the issues faced by Zambian prisoners are universal to prisoners worldwide.

Our results show it is feasible to deliver PrEP in diverse criminal justice settings where other HIV prevention commodities, such as condoms and lubricants, are prohibited. The approach was well received by justice-involved individuals, demonstrating high uptake among those eligible. To our knowledge, this is the first description of PrEP service delivery for people who are incarcerated in criminal justice settings in Sub-Saharan Africa."

Brianna R. Lindsay, MPH, PhD, Epidemiologist, Director of Health Programs at the Center for International Health, Education, and Biosecurity (Ciheb) at the Institute of Human Virology at UMSOM

In the study, the largest proportion of incarcerated people reached with HIV prevention services and initiated on PrEP were men between the ages of 25 and 29 years, consistent with the known demographics of the incarcerated population in Zambia. Prior to HIV testing, individuals were screened using a high-risk screening form. People who are incarcerated may be exposed to risks such as consensual and coerced sex, sexual violence, injection drug use, and tattooing. High-risk activity paired with other barriers to HIV prevention in prisons, including high inmate turnover, lack of health education, and the absence of HIV prevention tools, contributes to at least a 14 percent higher rate of infection than seen in the adult general population.

Funded by the U.S. President's Emergency Plan for AIDS Relief (USPFAR) through the U.S. Centers for Disease Control and Prevention (CDC), the study implemented PrEP through existing and previous projects that support HIV testing, and links participants, including people who are incarcerated, to treatment and service, such as the University of Maryland Baltimore-supported Community Impact to Reach Key and Underserved Individuals for Treatment and Support (CIRKUITS) and Zambia Community HIV Epidemic Control for Key Populations (Z-CHECK) programs. With an all-hands-on-deck approach, there was support for the study from all stakeholders, from the Correctional Service and Zambian Ministry of Health to the prison health committee and peer-led adherence support groups, to provide PrEP services.

To ensure a stable and continuous supply of PrEP medication, trained personnel worked with Zambia Ministry of Health supply chain teams to assess stock levels and support the distribution of HIV prevention supplies.

"We are honored to work with the Zambia Correctional Services and Ministry of Health to accomplish this initial implementation of PrEP at these facilities," said Cassidy W. Claassen, MD, MPH, Associate Professor of Medicine and Principal Investigator for this study, and Technical Director for the Zambia County Office at the Institute of Human Virology at UMSOM. "This represents one of the first such implementations anywhere in the world and marks an important step forward in demonstrating successful HIV prevention protocols for people who are incarcerated. "

Data was collected between October 1, 2020, to March 31, 2021, from 16 Zambian criminal justice facilities, involving a total of 12,367 people (of all sexes) in the study. Of all those who tested HIV negative and were screened for PrEP, 67 percent considered high risk were eligible to initiate. All PrEP participants participated voluntarily, and care was taken to avoid undue coercion or incentives. PrEP participation exceeded 90 percent among those eligible.

"Due to Ciheb's collaborative efforts with our partners to control HIV infection in Zambia, we have been able to help bring the HIV prevention and treatment rates to 98% across the country, and now we are focusing on targeting this previously and traditionally ignored population of people in prisons," said Manhattan Charurat, PhD, MHS, Professor of Medicine, Director of Ciheb, and Director of the Division of Epidemiology and Prevention at UMSOM's Institute of Human Virology.

"In many developing countries, it is much harder to institute plans for HIV interventions in prisons. However, we believe that our model can be successfully adapted to help control the spread and improve the health and well-being of inmates across the globe."

For future studies, the researchers plan to evaluate PrEP persistence and adherence, as well as the perceptions of people who are incarcerated regarding their HIV risk and preferences for combined HIV prevention services. They will also aim to assess and support PrEP adherence and persistence after these people are released from prison.

"There is an urgent need for health equity for all members of society. With almost 400,000 people globally incarcerated who are living with HIV, including 18,000 in the United States alone, controlling the spread of HIV in the prison system translates to healthier communities," said Dean Mark Gladwin, MD, who is also Vice President for Medical Affairs, University of Maryland, Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor. "What the team has accomplished in this study will hopefully accelerate further changes to the prison healthcare systems in Zambia and around the globe. "

Source:
Journal reference:

Lindsay, B., et al. (2022) Initial implementation of HIV pre-exposure prophylaxis for people who are incarcerated in Zambia: a cross-sectional observational study. The Lancet HIV. doi.org/10.1016/S2352-3018(22)00220-X.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Repurposing anti-retroviral medications for brain tumor treatment: The RETREAT trial